As a physician scientist, Eugenie Suter, MD, PhD, is dedicated to improving life for people with neurologic disorders. Her commitment
to drug development is founded on experience in research (Ph.D. in Neuroscience at Northwestern University; Immunology at Harvard's Boston Children's Hospital) as well as clinical medicine (Northwestern University; UCLA). Dr. Suter enjoys fostering innovation by drawing on her own experience and training in business, clinical trials, public policy and linguistics,. Driven by the need she witnesses clinically, she aims to bring new treatment options to individuals living with neurologic and other life-altering disorders through her work in Neuroscience & Rare Diseases as well as the Cardiovascular & Metabolic group at Roche.

Global pharmaceutical, OMP and pediatric EU legislation. Rare diseases policies . Gene Therapy-ATMP . HTA and access frameworks. Cross border access. Patient engagement. Incentives for medicine development. Repurposing.
- All aspects of medical affairs across the product life cycle - Compassionate Use and Medical Need programs. Diagnostics. Real world evidence and registries
- Multistakeholder engagement

I’m a generalist in a highly specialised environment and a Medical Doctor with over 25 years experience primarily in biotechnology and innovative pharmaceutical companies.

Strong international experience in medical and policy departments collaborate across functions and across stakeholders.

Experienced Patient Advocate active as a volunteer in the non-profit sector in Europe focused on rare diseases and especially rare eye disease. Background in finance and business strategy. Healthcare is in crisis and we need to collaborate to make things better - researchers, clinicians, regulators, payers, industry and patients, we all need to play our part. And across borders too - separatist nonsense like Brexit does not make anything better and we have to expend additional scarce resource to try and overcome the problems it creates

Roels inspiration: “Be the change you wish to see in the world” - Ghandi

Roel van der Heijde lives in Rotterdam, The Netherlands. He has a MA in International Business, is an international acknowledged NLP trainer, executive team coach and a certified death and grief counsellor.

He is a driven and experienced trainer and facilitator in:

• - Patient Fear Reduction (for all caregivers);
• - Team Collaboration;
• - Vulnerability & Leadership;
• - Discrimination & Inclusion.

Roels motivation: “Acknowledgement and recognition of the fears and emotions of our patients are the basis for excellent patient experience and patient safety”.

“Working with Groups I experience as thoroughly fascinating and inspiring. In interaction with groups I am every time amazed by the enormous potential of practical knowledge and direct experience that lies hidden in groups and that is so easily overlooked. Herein lies the basis for excellent vulnerable leadership.

A data driven, high performing and results orientated Team Leader, with 20+ years of experience in Strategic Planning and Programs Execution and with 15+ years of experience in direct management and development of teams and individuals, with a proven track record for delivering and optimizing clinical studies, leading high-performing teams in global, matrix-based environment across multiple therapeutic areas and compounds.

Expert in data analysis and interpretation, proficient in tools and technologies associated to project execution and recruitment strategies, and confident to work across different stakeholder groups to develop tactical/operational plans aligned with regulatory and commercial objectives.

Passionate about science, project management and people mentoring and improvement, with also a solid expertise in the regulation of clinical studies and data protection, risk assessment and root cause analysis, audits and implementation of CAPAs.

Accomplished Clinical Operations and Development Executive with an impressive track record, boasting hands-on experience in Clinical Development, (25 years in consultancy) Across all phases (I to IV), from translational medicine to lifecycle management.

Held pivotal roles including Program Management, Clinical Operations, Site Selection and Patient Recruitment, Regulatory Affairs, Safety Oversight, Medical Writing, and Clinical Quality Assurance.

Spearheaded and successfully navigated asset licensure initiatives.

Worked with a diverse client base ranging from medium-sized pharma companies to venture capital-backed startups.

Managed a workforce of up to 32 individuals, overseeing operations both domestically and internationally.

Possesses a global perspective, having lived and worked in diverse regions including the UK, Germany, Japan, and Australia. Proven ability to excel in culturally complex and logistically challenging geographies, as well as managing single protocol global studies.

Led strategic transformation initiatives by identifying opportunities for efficiency improvement, enhancing business performance, driving innovation through strategic thinking, cross-company leadership, change management expertise, and a profound knowledge of industry trends and best practices.

Actively served as a Corporate and Departmental Diversity, Equity, and Inclusion (DE&I) representative, emphasizing the importance of diversity and inclusion within the workplace.

Held the role of a guest lecturer at King's College London, contributing to the Masters in Clinical Research program.

Carl Bjartmar, M.D., Ph.D. CEO and co-founder of BjartmarMed AB. Experienced global pharma and biotech executive providing medical, scientific, and operational consulting expertise to private equity and small/medium companies in drug development, business development and due diligence. Key expertise clinical development within orphan, neuromuscular, neurology and oncology indications. Solid record of global leadership, including two IPOs on Nasdaq OMX, agreed clinical plans with FDA, EMA and PMDA, successful completion of phase I-IV studies, and new drug approvals. Between 2015 and 2018 Chief Medical Officer at Wilson Therapeutics AB, Stockholm, Sweden (acquisition by Alexion Pharmaceuticals in 2018 at 70% premium - USD 850m). Chief Medical Officer at Augustine Therapeutics, Leuven, Belgium. Board member of iCoat Medical AB. More than 30 international publications (peer-reviewed articles, review articles, book chapters).

Erela Dana BSc, MPhil, is the Director of Neurology at GlobalData based in London. Erela has extensive disease area analysis and forecasting experience coupled with a wide breadth of therapy area expertise drawing from her previous roles. Erela has over 10 years’ experience in pharma, biotech and medical device industries both in-house and in consulting. Her industry experience includes EMA product launching as well as integration of strategic multichannel marketing plans, specializing particularly on novel biologic products including immunotherapies. As part of her prior consultancy engagements Erela has worked on numerous projects at GlobalData as a principal consultant as well as during her time at IQVIA Financial Institution Consulting, Align Strategy and Informa Pharma Consulting focusing on commercial due diligences, market opportunity assessments and new product planning, and investment strategies, including transactional advisory provided to investment professionals. Erela holds a master’s degree (MPhil) in Bioscience Enterprise from University of Cambridge and a BSc in Biomedical Engineering from Johns Hopkins University.

Myles Dakin founded the research company, Hypo-Stream, to address anticipated needs in burns treatment and nosocomial infection with AMR pathogens.  His R&D journey has led to discovery of a multi-modal anti-inflammatory agent that neutralises both Il-6 and TNF-a alongside altering the ratio of Il-10 to Il-6 in a favourable way.  Hypo-Stream has progressed to an emerging pharma company with CHMP supported Ph III ready asset and orphan designation in a rare disease alongside a pipeline with potential global impact.

Jenifer Ngo Waldrop joined the Black Women’s Health Imperative (BWHI) as Executive Director of the Rare Disease Diversity Coalition (RDDC) in October 2022. Before joining the leadership team of RDDC, she developed models and programs for diversity, equity, and inclusion initiatives to support multiple business units with Fortune 500 companies and organizations in Asia, Canada, and the US.

Jenifer has led initiatives at non-profit organizations where she recruited local community members to participate in numerous health-related fundraising events and developed programs to target disparities and underrepresented groups. In addition to facilitating development and fundraising, Jenifer developed a reputation for successful coalition building.

Jenifer received her undergraduate degree from Colby College and her Master of Human Resources Development from Villanova. As the Professional Development Director of the National Association of Asian-American Professionals (NAAAP) of Colorado, Jenifer continues her outreach in society. Through this organization, she mentors formally and informally.